Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure

David Siegel; Gary J. Schiller; Christy Samaras; Michael Sebag; Jesus G. Berdeja; Siddhartha Ganguly; Jeffrey V. Matous; Kevin W Song; Christopher S. Seet; Giampaolo Talamo; Shanthi Srinivas; Mirelis Acosta-Rivera; Michael Bar; Donald Quick; Bertrand Anz; Gustavo Fonseca; Donna Reece; Jorge Mouro; Amit Agarwal; Faiza Zafar; Max Qian; Anjan Thakurta; Nizar J. Bahlis

doi:10.1182/BLOOD.V130.SUPPL_1.1811.1811

Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure

David Siegel
, Gary J. Schiller
, Christy Samaras
, Michael Sebag
, Jesus G. Berdeja
, Siddhartha Ganguly
, Jeffrey V. Matous
, Kevin W Song
, Christopher S. Seet
, Giampaolo Talamo
, Shanthi Srinivas
, Mirelis Acosta-Rivera
, Michael Bar
, Donald Quick
, Bertrand Anz
, Gustavo Fonseca
, Donna Reece
, Jorge Mouro
, Amit Agarwal
, Faiza Zafar

Max Qian, Anjan Thakurta, Nizar J. Bahlis

Hackensack University Medical Center
University of California, Los Angeles
Cleveland Clinic
Royal Victoria Hospital, Montreal, Canada
Tennessee Oncology, PLLC, Nashville, TN
University of Kansas
Colorado Blood Cancer Institute, Denver, CO
Vancouver General Hospital
UCLA Medical Center
Pennsylvania State University
United States Department of Veterans Affairs
Fundacion de Investigacion,, San Juan,, Puerto Rico
Stamford Hospital
Joe Arrington Caner Research Treatment Center, Lubbock, TX
17Tennessee Oncology, Chattanooga, TN
Florida Cancer Specialists, St Petersburg, FL
Princess Margaret Cancer Centre
Celgene
University of Calgary

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Blood
Volume	130
DOIs	https://doi.org/10.1182/BLOOD.V130.SUPPL_1.1811.1811
State	Published - Dec 7 2017
Externally published	Yes

Disciplines

Medicine and Health Sciences
Internal Medicine

Access to Document

10.1182/BLOOD.V130.SUPPL_1.1811.1811License: Unspecified

Cite this

Siegel, D., Schiller, G. J., Samaras, C., Sebag, M., Berdeja, J. G., Ganguly, S., Matous, J. V., Song, K. W., Seet, C. S., Talamo, G., Srinivas, S., Acosta-Rivera, M., Bar, M., Quick, D., Anz, B., Fonseca, G., Reece, D., Mouro, J., Agarwal, A., ... Bahlis, N. J. (2017). Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure. Blood, 130. https://doi.org/10.1182/BLOOD.V130.SUPPL_1.1811.1811

Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure. / Siegel, David; Schiller, Gary J.; Samaras, Christy et al.
In: Blood, Vol. 130, 07.12.2017.

Research output: Contribution to journal › Article › peer-review

Siegel, D, Schiller, GJ, Samaras, C, Sebag, M, Berdeja, JG, Ganguly, S, Matous, JV, Song, KW, Seet, CS, Talamo, G, Srinivas, S, Acosta-Rivera, M, Bar, M, Quick, D, Anz, B, Fonseca, G, Reece, D, Mouro, J, Agarwal, A, Zafar, F, Qian, M, Thakurta, A & Bahlis, NJ 2017, 'Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure', Blood, vol. 130. https://doi.org/10.1182/BLOOD.V130.SUPPL_1.1811.1811

Siegel D, Schiller GJ, Samaras C, Sebag M, Berdeja JG, Ganguly S et al. Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure. Blood. 2017 Dec 7;130. doi: 10.1182/BLOOD.V130.SUPPL_1.1811.1811

@article{9cd25d33f9e14233827ad9dc4c17575e,

title = "Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure",

author = "David Siegel and Schiller, \{Gary J.\} and Christy Samaras and Michael Sebag and Berdeja, \{Jesus G.\} and Siddhartha Ganguly and Matous, \{Jeffrey V.\} and Song, \{Kevin W\} and Seet, \{Christopher S.\} and Giampaolo Talamo and Shanthi Srinivas and Mirelis Acosta-Rivera and Michael Bar and Donald Quick and Bertrand Anz and Gustavo Fonseca and Donna Reece and Jorge Mouro and Amit Agarwal and Faiza Zafar and Max Qian and Anjan Thakurta and Bahlis, \{Nizar J.\}",

note = "David Siegel, Gary J. Schiller, Christy Samaras, Michael Sebag, Jesus G. Berdeja, Siddhartha Ganguly, Jeffrey V. Matous, Kevin W Song, Christopher S. Seet, Giampaolo Talamo, Shanthi Srinivas, Mirelis Acosta-Rivera, Michael Bar, Donald Quick, Bertrand Anz, Gustavo Fonseca, Donna Reece, Jorge Mouro, Amit Agarwal, Faiza Zafar, Max Qian, Anjan Thakurta, Nizar J.",

year = "2017",

month = dec,

day = "7",

doi = "10.1182/BLOOD.V130.SUPPL\_1.1811.1811",

language = "American English",

volume = "130",

journal = "Blood",

publisher = "American Society of Hematology",

}

TY - JOUR

T1 - Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure

AU - Siegel, David

AU - Schiller, Gary J.

AU - Samaras, Christy

AU - Sebag, Michael

AU - Berdeja, Jesus G.

AU - Ganguly, Siddhartha

AU - Matous, Jeffrey V.

AU - Song, Kevin W

AU - Seet, Christopher S.

AU - Talamo, Giampaolo

AU - Srinivas, Shanthi

AU - Acosta-Rivera, Mirelis

AU - Bar, Michael

AU - Quick, Donald

AU - Anz, Bertrand

AU - Fonseca, Gustavo

AU - Reece, Donna

AU - Mouro, Jorge

AU - Agarwal, Amit

AU - Zafar, Faiza

AU - Qian, Max

AU - Thakurta, Anjan

AU - Bahlis, Nizar J.

N1 - David Siegel, Gary J. Schiller, Christy Samaras, Michael Sebag, Jesus G. Berdeja, Siddhartha Ganguly, Jeffrey V. Matous, Kevin W Song, Christopher S. Seet, Giampaolo Talamo, Shanthi Srinivas, Mirelis Acosta-Rivera, Michael Bar, Donald Quick, Bertrand Anz, Gustavo Fonseca, Donna Reece, Jorge Mouro, Amit Agarwal, Faiza Zafar, Max Qian, Anjan Thakurta, Nizar J.

PY - 2017/12/7

Y1 - 2017/12/7

UR - https://ashpublications.org/blood/article/130/Supplement%201/1811/79407/Safety-and-Efficacy-of-Pomalidomide-POM-Low-Dose

U2 - 10.1182/BLOOD.V130.SUPPL_1.1811.1811

DO - 10.1182/BLOOD.V130.SUPPL_1.1811.1811

M3 - Article

VL - 130

JO - Blood

JF - Blood

ER -

Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure

Disciplines

Access to Document

Other files and links

Cite this